FDA Warns It Will Take Action on Misleading Copycat Drug Marketing
The United States Food and Drug Administration (FDA) has warned it will take swift action against companies that mass-market unapproved “copycat” drugs by promoting them as if they were similar to FDA-approved products, the agency’s commissioner said.
FDA Commissioner Marty Makary | 06/02/2026 | By Darshana
FDA Launches 'Green List' to Crack Down on Illegal GLP-1 API Imports
The US Food and Drug Administration (FDA) has created a new “green list” import alert to stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the US market.
FDA Commissioner Marty Makary | 09/09/2025 | By Dineshwori | 785
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy